SCHEMBL5137489

SCHEMBL5137489

CCCCN(Cc1ccc(-c2ccccc2)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.48
TSHR P16473 5/20 0.45
HSD11B1 P28845 2/20 0.41
ATP4A P20648 3/20 0.41
ATP4B P51164 3/20 0.41
CRHR1 P34998 2/20 0.41
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP3A4 P08684 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135570 0.96 C5AR1 (0.48) C5AR1TSHRHSD11B1ATP4AATP4B
SCHEMBL649161 0.95 C5AR1 (0.47) C5AR1TSHRATP4AATP4BCRHR1
SCHEMBL5135824 0.95 C5AR1 (0.44) C5AR1TSHRHSD11B1ATP4AATP4B
SCHEMBL5070130 0.94 C5AR1 (0.47) C5AR1TSHRHSD11B1ATP4AATP4B
SCHEMBL5072249 0.94 C5AR1 (0.47) C5AR1TSHRHSD11B1ATP4AATP4B
Hydrochloric Acid SCHEMBL648480 0.94 C5AR1 (0.46) C5AR1TSHRATP4AATP4BCRHR1
SCHEMBL5134950 0.94 C5AR1 (0.45) C5AR1TSHRHSD11B1ATP4AATP4B
SCHEMBL5135922 0.93 C5AR1 (0.49) C5AR1TSHRHSD11B1KDM4EALDH1A1
SCHEMBL5137989 0.93 C5AR1 (0.46) C5AR1TSHRHSD11B1ATP4AATP4B
SCHEMBL5136524 0.93 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed